보로노이

310210KOSDAQSector: Pharma & Biotech

₩126,200▼ 6.52%Market cap ₩2.32TAs of Jul 21, 2026 close · updated once daily

Grade D29.5 ptsTop 87% of 2,523 stocks

Financial strength

40.1

Growth momentum

15.1

Price attractiveness

27.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

40.1

How much debt does it carry relative to equity?

Debt-to-equity ratio

65.0%

✗ Below median · Top 60.8% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

1877.9%

✓ Above median · Top 5.1% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-723.9%

✗ Below median · Top 94% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-41.1%

✗ Below median · Top 79.9% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

15.1

Has it grown steadily over three years?

Revenue 3-year CAGR

-8.4%

✗ Below median · Top 82.7% in sector

Sector median 4.9%

Did core profits grow in a year?

Operating income change (YoY)

-49.7%

✗ Below median · Top 81.9% in sector

Sector median 3.6%

Are core profits higher than three years ago?

Operating income change (3Y)

-204.4%

✗ Below median · Top 90.1% in sector

Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

27.7

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 52.2% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

22.42x

✗ Below median · Top 92.5% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15